Edition:
United States

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

9.89USD
4:00pm EDT
Change (% chg)

$-1.03 (-9.43%)
Prev Close
$10.92
Open
$10.92
Day's High
$11.05
Day's Low
$9.85
Volume
472,556
Avg. Vol
331,374
52-wk High
$19.80
52-wk Low
$6.60

Latest Key Developments (Source: Significant Developments)

Iovance Announces Proposed Public Offering Of Common Stock
Thursday, 11 Oct 2018 04:05pm EDT 

Oct 11 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.IOVANCE BIOTHERAPEUTICS - INTENDS TO USE PROCEEDS FROM OFFERING TO FUND EXPANSION OF ORGANIZATION TO SUPPORT POTENTIAL COMMERCIAL LAUNCH OF LIFILEUCEL.IOVANCE - INTENDS TO USE PROCEEDINGS FROM OFFERING TO FUND COMMERCIAL MANUFACTURING CAPABILITIES, ONGOING CLINICAL TRIALS FOR CURRENT PRODUCT CANDIDATES.  Full Article

Iovance Biotherapeutics Reports Results From FDA End Of Phase 2 Meeting
Thursday, 11 Oct 2018 04:00pm EDT 

Oct 11 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS REPORTS RESULTS FROM FDA END OF PHASE 2 MEETING AND PROVIDES UPDATES ABOUT THE COMPANY’S CLINICAL PROGRAM.IOVANCE BIOTHERAPEUTICS - FDA RECOMMENDED AMENDING EXISTING ONGOING PHASE 2 STUDY C-144-01 TO ADD A REGISTRATION-ENABLING COHORT (COHORT 4).IOVANCE BIOTHERAPEUTICS INC - COHORT 4 ENROLLMENT IS EXPECTED TO BEGIN EARLY 2019 WITH A BLA SUBMISSION EXPECTED IN SECOND HALF OF 2020.IOVANCE BIOTHERAPEUTICS INC - FDA HAS FURTHER ACKNOWLEDGED THAT CONDUCT OF A RANDOMIZED PHASE 3 TRIAL MAY NOT BE FEASIBLE.IOVANCE BIOTHERAPEUTICS-TO CONTINUE CONSULTATION WITH FDA UNDER RMAT DESIGNATION & ENROLL NEW COHORT OF PATIENTS TO SUPPORT REGISTRATION OF LIFILEUCEL.IOVANCE BIOTHERAPEUTICS INC - ALIGNMENT WITH FDA REGARDING ACCEPTABILITY OF A SINGLE-ARM COHORT TO SUPPORT REGISTRATION OF LEAD PRODUCT.IOVANCE BIOTHERAPEUTICS INC - FOR 46 PATIENTS, AN OBJECTIVE RESPONSE RATE (ORR) OF 37% HAS BEEN OBSERVED IN COHORT.IOVANCE BIOTHERAPEUTICS INC - OBJECTIVE RESPONSE RATE INCLUDES A COMPLETE RESPONSE AND 16 PARTIAL RESPONSES IN STUDY.IOVANCE BIOTHERAPEUTICS INC - FDA HAS ACKNOWLEDGED POTENTIAL ACCEPTABILITY OF A SINGLE-ARM COHORT FOR REGISTRATION.  Full Article

Iovance Biotherapeutics Reports Q4 Non-Gaap Loss Per Share $0.32
Monday, 12 Mar 2018 04:01pm EDT 

March 12 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 NON-GAAP LOSS PER SHARE $0.32.Q4 GAAP LOSS PER SHARE $0.36.Q4 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.IOVANCE - ANTICIPATES CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE BETWEEN $190 MILLION AND $210 MILLION AT DECEMBER 31.  Full Article

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 07:05am EST 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics
Wednesday, 13 Dec 2017 06:30am EST 

Dec 13 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS.BIOLIFE SOLUTIONS - EXECUTED AGREEMENT TO SUPPLY CRYOSTOR CELL FREEZE MEDIA AND HYPOTHERMOSOL STORAGE AND SHIPPING MEDIA TO IOVANCE BIOTHERAPEUTICS.  Full Article

Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35
Tuesday, 31 Oct 2017 04:01pm EDT 

Oct 31 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics Inc reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.31.Q3 GAAP loss per share $0.35.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Iovance Biotherapeutics Inc - ‍anticipates cash, cash equivalents and short-term investments as of December 31, 2017, to be in excess of $141.0 million​.  Full Article

Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock
Wednesday, 20 Sep 2017 06:07pm EDT 

Sept 20 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics, Inc. announces pricing of its public offering of $50 million of common stock.Iovance Biotherapeutics- Announced pricing of underwritten public offering of 7.7 million shares of common stock at public offering price of $6.50/share.  Full Article

Iovance BioTherapeutics plans to offer $50 mln of common stock​
Tuesday, 19 Sep 2017 04:35pm EDT 

Sept 19 (Reuters) - Iovance Biotherapeutics Inc :Intends to offer and sell $50 million of its common stock​.Intends to use proceeds from this offering to fund its ongoing clinical trials for its current candidates​.  Full Article

Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer
Wednesday, 13 Sep 2017 08:00am EDT 

Sept 13 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics announces approval of first clinical trial application by competent authority in Netherlands for a phase 2 trial of LN-145 for the treatment of patients with cervical cancer.  Full Article

Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center
Thursday, 7 Sep 2017 08:00am EDT 

Sept 7 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center.‍Collaboration will initially focus on hematologic malignancies in areas of poor prognostic cancers​.  Full Article